AFFINITY BINDING ENTITIES DIRECTED TO CD70 AND METHODS OF USE THEREOF
Aspects of the disclosure include compositions and methods for the treatment of CD70-expressing tumors with engineered γδ T-cells. In embodiments, the γδ T-cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can include a full-length CD27 receptor domain, a costimulatory do...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | TEAGUE, Alexander BHAT, Arun SPELTZ, Elizabeth NISHIMOTO, Kevin DING, Beibei RAMADOSS, Nitya AFTAB, Blake LAMTURE, Gauri |
| description | Aspects of the disclosure include compositions and methods for the treatment of CD70-expressing tumors with engineered γδ T-cells. In embodiments, the γδ T-cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can include a full-length CD27 receptor domain, a costimulatory domain, an intracellular signaling domain, a combination thereof, or all thereof. The CAR construct can contain a domain encoding for an additional polypeptide that confers advantageous functionality to the γδ T- cells.
Des aspects de l'invention comprennent des compositions et des méthodes pour le traitement de tumeurs exprimant CD70 avec des lymphocytes T γδ modifiés. Dans des modes de réalisation, les lymphocytes T γδ comprennent une construction de récepteur antigénique chimérique (CAR). La construction CAR peut comprendre un domaine récepteur CD27 pleine longueur, un domaine costimulateur, un domaine de signalisation intracellulaire, une combinaison de ceux-ci, ou l'ensemble de ceux-ci. La construction CAR peut contenir un codage de domaine pour un polypeptide supplémentaire qui confère une fonctionnalité avantageuse aux lymphocytes T γδ. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2024026127A2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2024026127A2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2024026127A23</originalsourceid><addsrcrecordid>eNqNyrEKwjAQANAsDqL-w4GzEKPYOc1dzA3moDkRp1JKnEQL9f9x8QOc3vKWhnyMnFnv0HJGzmegrKxMBZA7CkoIKhCwseAzwoU0CRaQCNdCoIk6krg2i8fwnOvm58psI2lIuzq9-zpPw1hf9dPfxFl3tO60d413h__WF-7WLFc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>AFFINITY BINDING ENTITIES DIRECTED TO CD70 AND METHODS OF USE THEREOF</title><source>esp@cenet</source><creator>TEAGUE, Alexander ; BHAT, Arun ; SPELTZ, Elizabeth ; NISHIMOTO, Kevin ; DING, Beibei ; RAMADOSS, Nitya ; AFTAB, Blake ; LAMTURE, Gauri</creator><creatorcontrib>TEAGUE, Alexander ; BHAT, Arun ; SPELTZ, Elizabeth ; NISHIMOTO, Kevin ; DING, Beibei ; RAMADOSS, Nitya ; AFTAB, Blake ; LAMTURE, Gauri</creatorcontrib><description>Aspects of the disclosure include compositions and methods for the treatment of CD70-expressing tumors with engineered γδ T-cells. In embodiments, the γδ T-cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can include a full-length CD27 receptor domain, a costimulatory domain, an intracellular signaling domain, a combination thereof, or all thereof. The CAR construct can contain a domain encoding for an additional polypeptide that confers advantageous functionality to the γδ T- cells.
Des aspects de l'invention comprennent des compositions et des méthodes pour le traitement de tumeurs exprimant CD70 avec des lymphocytes T γδ modifiés. Dans des modes de réalisation, les lymphocytes T γδ comprennent une construction de récepteur antigénique chimérique (CAR). La construction CAR peut comprendre un domaine récepteur CD27 pleine longueur, un domaine costimulateur, un domaine de signalisation intracellulaire, une combinaison de ceux-ci, ou l'ensemble de ceux-ci. La construction CAR peut contenir un codage de domaine pour un polypeptide supplémentaire qui confère une fonctionnalité avantageuse aux lymphocytes T γδ.</description><language>eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240201&DB=EPODOC&CC=WO&NR=2024026127A2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240201&DB=EPODOC&CC=WO&NR=2024026127A2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>TEAGUE, Alexander</creatorcontrib><creatorcontrib>BHAT, Arun</creatorcontrib><creatorcontrib>SPELTZ, Elizabeth</creatorcontrib><creatorcontrib>NISHIMOTO, Kevin</creatorcontrib><creatorcontrib>DING, Beibei</creatorcontrib><creatorcontrib>RAMADOSS, Nitya</creatorcontrib><creatorcontrib>AFTAB, Blake</creatorcontrib><creatorcontrib>LAMTURE, Gauri</creatorcontrib><title>AFFINITY BINDING ENTITIES DIRECTED TO CD70 AND METHODS OF USE THEREOF</title><description>Aspects of the disclosure include compositions and methods for the treatment of CD70-expressing tumors with engineered γδ T-cells. In embodiments, the γδ T-cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can include a full-length CD27 receptor domain, a costimulatory domain, an intracellular signaling domain, a combination thereof, or all thereof. The CAR construct can contain a domain encoding for an additional polypeptide that confers advantageous functionality to the γδ T- cells.
Des aspects de l'invention comprennent des compositions et des méthodes pour le traitement de tumeurs exprimant CD70 avec des lymphocytes T γδ modifiés. Dans des modes de réalisation, les lymphocytes T γδ comprennent une construction de récepteur antigénique chimérique (CAR). La construction CAR peut comprendre un domaine récepteur CD27 pleine longueur, un domaine costimulateur, un domaine de signalisation intracellulaire, une combinaison de ceux-ci, ou l'ensemble de ceux-ci. La construction CAR peut contenir un codage de domaine pour un polypeptide supplémentaire qui confère une fonctionnalité avantageuse aux lymphocytes T γδ.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyrEKwjAQANAsDqL-w4GzEKPYOc1dzA3moDkRp1JKnEQL9f9x8QOc3vKWhnyMnFnv0HJGzmegrKxMBZA7CkoIKhCwseAzwoU0CRaQCNdCoIk6krg2i8fwnOvm58psI2lIuzq9-zpPw1hf9dPfxFl3tO60d413h__WF-7WLFc</recordid><startdate>20240201</startdate><enddate>20240201</enddate><creator>TEAGUE, Alexander</creator><creator>BHAT, Arun</creator><creator>SPELTZ, Elizabeth</creator><creator>NISHIMOTO, Kevin</creator><creator>DING, Beibei</creator><creator>RAMADOSS, Nitya</creator><creator>AFTAB, Blake</creator><creator>LAMTURE, Gauri</creator><scope>EVB</scope></search><sort><creationdate>20240201</creationdate><title>AFFINITY BINDING ENTITIES DIRECTED TO CD70 AND METHODS OF USE THEREOF</title><author>TEAGUE, Alexander ; BHAT, Arun ; SPELTZ, Elizabeth ; NISHIMOTO, Kevin ; DING, Beibei ; RAMADOSS, Nitya ; AFTAB, Blake ; LAMTURE, Gauri</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2024026127A23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>TEAGUE, Alexander</creatorcontrib><creatorcontrib>BHAT, Arun</creatorcontrib><creatorcontrib>SPELTZ, Elizabeth</creatorcontrib><creatorcontrib>NISHIMOTO, Kevin</creatorcontrib><creatorcontrib>DING, Beibei</creatorcontrib><creatorcontrib>RAMADOSS, Nitya</creatorcontrib><creatorcontrib>AFTAB, Blake</creatorcontrib><creatorcontrib>LAMTURE, Gauri</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>TEAGUE, Alexander</au><au>BHAT, Arun</au><au>SPELTZ, Elizabeth</au><au>NISHIMOTO, Kevin</au><au>DING, Beibei</au><au>RAMADOSS, Nitya</au><au>AFTAB, Blake</au><au>LAMTURE, Gauri</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>AFFINITY BINDING ENTITIES DIRECTED TO CD70 AND METHODS OF USE THEREOF</title><date>2024-02-01</date><risdate>2024</risdate><abstract>Aspects of the disclosure include compositions and methods for the treatment of CD70-expressing tumors with engineered γδ T-cells. In embodiments, the γδ T-cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can include a full-length CD27 receptor domain, a costimulatory domain, an intracellular signaling domain, a combination thereof, or all thereof. The CAR construct can contain a domain encoding for an additional polypeptide that confers advantageous functionality to the γδ T- cells.
Des aspects de l'invention comprennent des compositions et des méthodes pour le traitement de tumeurs exprimant CD70 avec des lymphocytes T γδ modifiés. Dans des modes de réalisation, les lymphocytes T γδ comprennent une construction de récepteur antigénique chimérique (CAR). La construction CAR peut comprendre un domaine récepteur CD27 pleine longueur, un domaine costimulateur, un domaine de signalisation intracellulaire, une combinaison de ceux-ci, ou l'ensemble de ceux-ci. La construction CAR peut contenir un codage de domaine pour un polypeptide supplémentaire qui confère une fonctionnalité avantageuse aux lymphocytes T γδ.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2024026127A2 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | AFFINITY BINDING ENTITIES DIRECTED TO CD70 AND METHODS OF USE THEREOF |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T12%3A14%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=TEAGUE,%20Alexander&rft.date=2024-02-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2024026127A2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |